» Articles » PMID: 10654072

Effect of Cholecystokinin-2 Receptor Blockade on Rat Stomach ECL Cells. A Histochemical, Electron-microscopic and Chemical Study

Overview
Journal Cell Tissue Res
Date 2000 Feb 2
PMID 10654072
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The ECL cells in the oxyntic mucosa of rat stomach produce histamine and chromogranin A-derived peptides such as pancreastatin. The cells respond to gastrin via cholecystokinin-2 (CCK2) receptors. A CCK2 receptor blockade was induced by treatment (for up to 8 weeks) with two receptor antagonists, YM022 and YF476. Changes in ECL-cell morphology were examined by immunocytochemistry and electron microscopy, while changes in ECL cell-related biochemical parameters were monitored by measuring serum pancreastatin and oxyntic mucosal pancreastatin, and histamine concentrations, and histidine decarboxylase (HDC) activity. The CCK2 receptor blockade reduced the ECL-cell density only marginally, if at all, but transformed the ECL cells from slender, elongated cells with prominent projections to small, spherical cells without projections. The Golgi complex and the rough endoplasmic reticulum were diminished. Secretory vesicles were greatly reduced in volume density in the trans Golgi area. Circulating pancreastatin concentration and oxyntic mucosal HDC activity were lowered within a few hours. Oxyntic mucosal histamine and pancreastatin concentrations were reduced only gradually. The CCK2 receptor blockade was found to prevent the effects of omeprazole-evoked hypergastrinaemia on the ECL-cell activity and density. In conclusion, gastrin, acting on CCK2 receptors, is needed to maintain the shape, size and activity of the ECL cells, but not for maintaining the ECL-cell population.

Citing Articles

Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology.

Chen D, Hagen S, Boyce M, Zhao C J Neuroendocrinol. 2023; 35(11):e13305.

PMID: 37317882 PMC: 10656367. DOI: 10.1111/jne.13305.


Hypergastrinemia Expands Gastric ECL Cells Through CCK2R Progenitor Cells via ERK Activation.

Sheng W, Malagola E, Nienhuser H, Zhang Z, Kim W, Zamechek L Cell Mol Gastroenterol Hepatol. 2020; 10(2):434-449.e1.

PMID: 32330731 PMC: 7371950. DOI: 10.1016/j.jcmgh.2020.04.008.


Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.

Boyce M, Moore A, Sagatun L, Parsons B, Varro A, Campbell F Br J Clin Pharmacol. 2016; 83(3):466-475.

PMID: 27704617 PMC: 5306499. DOI: 10.1111/bcp.13146.


Deletion of and induces hypergastrinemia and gastric carcinoids.

Sundaresan S, Kang A, Hayes M, Choi E, Merchant J Gut. 2016; 66(6):1012-1021.

PMID: 26860771 PMC: 4980289. DOI: 10.1136/gutjnl-2015-310928.


Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.

Boyce M, Dowen S, Turnbull G, van den Berg F, Zhao C, Chen D Br J Clin Pharmacol. 2014; 79(5):744-55.

PMID: 25335860 PMC: 4415711. DOI: 10.1111/bcp.12534.